• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Otsuka, Lundbeck Receive FDA Approval for New Alzheimer’s Medication

Article

Rexulti to be first authorized treatment for agitation associated with dementia.

Care worker helping elderly woman to walk in geriatric hospice. Image Credit: Adobe Stock Images/New Africa

Image Credit: Adobe Stock Images/New Africa

Otsuka Pharmaceutical, a global healthcare company, has received FDA approval for a new dementia drug in association with Lundbeck, a pharmaceutical organization specializing in brain diseases. As the first of its kind to be authorized, Rexulti focuses on combating agitation for those with Alzheimer’s disease.

Previously, the FDA granted Rexulti priority review, designating it a significant improvement in the effectiveness of a treatment.

“This approval is a testament to our commitment and unwavering support of patients and caregivers to lessen the symptoms of agitation associated with dementia due to Alzheimer’s disease,” said Deborah Dunsire, CEO, president, Lundbeck. “We look forward to offering this first FDA-approved treatment option to address this significant unmet need for patients.”

Related Videos
Related Content